DOCSLIB.ORG

Hormonal Pathology of the Endometrium Liane Deligdisch, M.D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hormonal Pathology of the Endometrium Liane Deligdisch, M.D THE 1999 LONG COURSE ON PATHOLOGY OF THE UTERINE CORPUS AND CERVIX Hormonal Pathology of the Endometrium Liane Deligdisch, M.D. Departments of Pathology and Obstetrics-Gynecology and Reproductive Science, The Mount Sinai–NYU Medical Center, New York, New York plastic changes may persist and coexist with secre- The endometrial tissue is a sensitive target for ste- tory changes. roid sex hormones and is able to modify its struc- Lupron therapy produces a shrinking of uterine tural characteristics with promptness and versatil- leiomyomas by accelerating their hyaline degener- ity. This article discusses briefly endogenous ation, similar to that in postmenopausal involution. hormonal effects (cyclic changes, luteal phase de- It generally produces endometrial atrophy. fect, unopposed estrogen effect) and describes the Tamoxifen for breast carcinoma has an estrogen- histologic patterns encountered in the most com- agonist effect on the uterus in approximately 20% of monly used hormone therapies: oral contracep- patients, who develop endometrial polyps, glandu- tives, ovulation stimulation, hormone replacement lar hyperplasia, adenomyosis, and/or leiomyomata. therapy, and antitumoral hormone therapy. Both endometrioid and nonendometrioid carcino- Oral contraceptives exert a predominant proges- mas are seen, often in polyps. Their causal relation- tational effect on the endometriun, inducing an ar- ship to tamoxifen therapy is debatable. rest of glandular proliferation, pseudosecretion, and stromal edema followed by decidualized Mod Pathol 2000;13(3):285–294 stroma with granulocytes and thin sinusoidal blood vessels. Prolonged use results in progressive endo- Hormone therapy is widely used throughout the metrial atrophy. world by women of all ages for a variety of reasons, Ovulation induction therapy accelerates the mat- ranging from oral contraception and ovulation uration of the stroma and is often associated with a stimulation for family planning to hormone re- discrepancy between early secretory glands and an placement therapy in menopause, to adjuvant ther- edematous or decidualized stroma with spiral arte- apy of tumors of the breast and uterus. The his- rioles. topathologic changes of the uterus, and particularly Hormone replacement therapy with estrogen of the endometrium, associated with these thera- alone may result in continuous endometrial prolif- pies encompass a variety of morphologic features eration, hyperplasia, and neoplasia. The use of both that are often difficult to interpret. The endome- estrogen and progesterone elicits a wide range of trium is a sensitive target tissue for steroid sex histologic patterns, seen in various combinations: hormones and is able to modify its structural char- proliferative and secretory changes, often mixed in acteristics with promptness and versatility. The the same tissue sample; glandular hyperplasia (in physiologic changes of the endometrium during polyps or diffuse) ranging from simple to complex reproductive life and after menopause reflect the atypical; stromal hyperplasia and/or decidual trans- influence of ovarian-secreted steroid sex hormones formation; epithelial metaplasia (eosinophilic, cili- and of their withdrawal. Hormone manipulation in ated, mucinous); and inactive and atrophic endo- fertility problems and hormonal substitution ther- metrium. apy result in histologic patterns that do not fit the Progesterone therapy for endometrial hyperpla- classical descriptions of the cyclic and involutional sia and neoplasia induces glandular secretory changes of the endometrium. Various combina- changes, decidual reaction, and spiral arterioles. tions of hyperplastic, proliferative, secretory, and atrophic changes of endometrial glands, stroma, Glandular proliferation is usually arrested, but neo- and blood vessels may result in confusing histologic patterns. As hormone therapy changes over time, with new regimens continuously being imple- Copyright © 2000 by The United States and Canadian Academy of Pathology, Inc. mented, the effect on the endometrium can result VOL. 13, NO. 3, P. 285, 2000 Printed in the U.S.A. in unpredictable structural changes. Date of acceptance: November 8, 1999. Address reprint requests to: Liane Deligdisch, M.D., Mount Sinai Medical The histologic patterns of the endometrium as- Center, Department of Pathology, One Gustave Levy Place, New York, NY sociated with hormone therapy vary with the dos- 10029. age, duration of therapy, and individual hormone receptor activity. The same endometrium may dis- 285 play a number of changes under different condi- The secretory activity in the second half of the tions, resulting in a diversity of histologic patterns menstrual cycle is characterized by a diversity of that may render some endometrial biopsies diffi- structural changes that are apparent on routine cult to interpret. Although the endometrial re- examination of endometrial biopsies, showing a sponse may vary from patient to patient, certain different pattern on every day of the cycle. “Dating” general histologic patterns for specific hormone the endometrium is identifying morphologic therapies can be recognized. To comprehend the changes characteristic for early, middle, and late iatrogenic effect of exogenous hormone therapy, a proliferative endometrium and for each of the 14 review of the normal and abnormal endogenous days of secretory endometrium (1, 2). hormone-related endometrial changes is appropri- Perhaps the most significant change in terms of ate. adequacy of the luteal phase is that involving the blood vessels. The thin endometrial arterioles un- ENDOMETRIAL MORPHOLOGY AND dergo a process of endothelial proliferation, thick- PATHOPHYSIOLOGY ening of the wall, and coiling forming the spiral arterioles on the ninth postovulatory day. These Before puberty, the endometrial tissue is inactive; arterioles have a critical role in the process of im- it is composed of tubular glands, a dense fibroblas- plantation because of the tropism for arterial blood tic stroma, and thin blood vessels. The advent of that characterizes trophoblastic tissue. Their coiling cyclic pituitary and ovarian hormonal activity re- increases the surface to be “tapped” by the im- sults in endometrial cyclic morphologic changes planting trophoblast; therefore, the chances for a involving glands, stroma, and blood vessels that can normal implantation are reduced if the spiral arte- be identified as characteristic for each day of the rioles are not well developed. The evaluation of cycle. endometrial biopsies properly performed a few In normal cycles, the menstrual shedding is fol- days before the onset of menstrual shedding is one lowed by endometrial proliferation under estro- of the most important diagnostic tools in the genic stimulation. The endometrial thickness in- work-up of infertility: It offers an insight into the creases more than 10-fold as a result of active tissue that will play host to the implanting concep- growth of glands, stroma, and blood vessels. The tus, assessing its adequacy. proliferative phase has a variable length from 10 to Pathologists are often asked to evaluate luteal 20 days, with an ideal duration of 14 days. During phase defects (LPD) in their reports on endometrial this phase, the endometrial glands grow and be- biopsies. LPD considered to be due to an inade- come tortuous because of the active proliferation of quate progesterone production is clinically some- epithelial cells. These estrogen-induced changes times associated with infertility and with spontane- occur as a response to the binding of the hormone ous abortions. Histologically, the maturation of the to nuclear receptors. The presence of estrogen re- endometrium is most commonly associated with a ceptors in the nuclei of endometrial cells is respon- lag of more than 2 days of the histologic date from sible for the prompt translation of hormonal im- the actual postovulatory date, possibly the result of pulses into structural changes, including, at an delayed ovulation (3). In insufficient follicle matu- ultrastructural level, protein synthesis by free ribo- ration, the endometrium appears immature; in per- somes and by the rough endoplasmic reticulum sistent graafian follicle, proliferative changes persist and accumulation of intermediate filaments, mito- throughout the secretory phase. A dissociation be- chondria, Golgi apparatus, and lysosomes. The nu- tween glandular and stromal maturation can also clei increase in size, nucleoli become prominent, be seen in LPD (see Table 1). The pathogenesis of and chromatin is coarse. The individual cell mass LPD is not completely understood. It may occur increases as does the nuclear-cytoplasmic ratio. when the corpus luteum fails to develop adequately Numerous mitoses are seen throughout the glands or as a result of deficient progesterone receptors. To and stroma. be diagnostically significant, LPD has to be found in After ovulation, the secretion of progesterone in- at least two consecutive cycles (3). hibits the proliferative activity of the endometrium and induces a complex secretory activity starting with the polarization of glycogen at a subnuclear TABLE 1. Luteal Phase Defect location followed by its transport via microfila- Ovarian Changes Endometrial Changes ments to the apical region of the cell. The Golgi Delayed ovulation Ͼ2-day delay in maturation apparatus “packages” the glycogen and various Insufficient follicle maturation Thin endometrium, low glycogen, thin arterioles, tubular glands other substances, which become secretory
Load more

Recommended publications
  • Prospective Study on Gynaecological Effects of Two Antioestrogens Tamoxifen and Toremifene in Postmenopausal Women
    British Journal of Cancer (2001) 84(7), 897–902 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2001.1703, available online at http://www.idealibrary.com on http://www.bjcancer.com Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women MB Marttunen1, B Cacciatore1, P Hietanen2, S Pyrhönen2, A Tiitinen1, T Wahlström3 and O Ylikorkala1 1Departments of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland; 2Department of Oncology, Helsinki University Central Hospital, P.O. Box 180, FIN-00029 HYKS, Finland; 3Department of Pathology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland Summary To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II–III breast cancer. Detailed interview concerning menopausal symptoms, pelvic examination including transvaginal sonography (TVS) and collection of endometrial sample were performed at baseline and at 6, 12, 24 and 36 months of treatment. In a subgroup of 30 women (15 using tamoxifen and 15 toremifene) pulsatility index (PI) in an uterine artery was measured before and at 6 and 12 months of treatment. The mean (±SD) follow-up time was 2.3 ± 0.8 years. 35% of the patients complained of vasomotor symptoms before the start of the trial. This rate increased to 60.0% during the first year of the trial, being similar among patients using tamoxifen (57.1%) and toremifene (62.7%).
    [Show full text]
  • Differential Studies of Ovarian Endometriosis Cells from Endometrium Or Oviduct
    European Review for Medical and Pharmacological Sciences 2016; 20: 2769-2772 Differential studies of ovarian endometriosis cells from endometrium or oviduct W. LIU1,2, H.-Y. WANG3 1Reproductive Center, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China 2Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Medical University of Anhui, Hefei, Anhui, China 3Department of Gynecologic Oncology, Anhui Provincial Cancer Hospital, the West Branch of Anhui Provincial Hospital, Hefei, Anhui, China Abstract. – OBJECTIVE: To study the promi- In most cases, EMT affects ovary and peritone- nent differences between endometriosis (EMT) um, and as a result a plump shape cyst forms in cells derived from ovary, oviduct and endometri- the ovary. The cyst is called ovarian endometrio- um, and to provided new ideas about the patho- sis cyst (aka ovarian chocolate cyst) which usually genesis of endometriosis. PATIENTS AND METHODS: contains old blood and is covered by endometrioid From June 2010 1 to June 2015, 210 patients diagnosed with en- epithelium. In 1860, Karl von Rokitansky studied dometriosis were enrolled in our study. Patients the disease and observed retrograde menstruation were treated by laparoscopy or conventional in nearly 90% of child-bearing women, and later surgeries in our hospital. Ovarian chocolate proposed “retrograde menstruation implantation cyst and paired normal ovarian tissues, fimbri- theory”. However, this theory explained endo- ated extremity of fallopian and uterine cavity en- metriosis in the abdominopelvic cavity does not domembrane tissues were collected, prepared 2 and observed by microscope. PCR was used for explain endometriosis outside of enterocelia . Lat- 3 4 amplification of target genes (FMO3 and HOXA9) er on, Iwanoff and Meyer proposed “coelomic and Western blot was used to evaluate FMO3 metaplasia theory” which stipulated that endome- and HOXA9 expression levels.
    [Show full text]
  • Tamoxifen, Raloxifene Upheld for Prevention
    38 WOMEN’S HEALTH MAY 1, 2010 • FAMILY PRACTICE NEWS Tamoxifen, Raloxifene Upheld for Prevention BY KERRI WACHTER 9,736 on tamoxifen and 9,754 on ralox- 1.24, which was significant (P = .01). Both events) did not appear to be as effective ifene. The differences in numbers are due drugs reduced the risk of invasive breast as tamoxifen (57 events) in preventing WASHINGTON — Tamoxifen and to a combination of loss during follow- cancer by roughly 50% in the original re- noninvasive breast cancer (P = .052). raloxifene offer women at high risk of up or follow-up data becoming available port (median follow-up 47 months). “Now with additional follow-up, those developing breast cancer two effective for women who were lost to follow-up “We have estimated, however, that differences have narrowed,” he said. At options to prevent the disease, based on in the original report. Women on ta- this difference in the raloxifene-treated 8 years, there was no statistical signifi- 8 years of follow-up data for more than moxifen received 20 mg/day and those group represents 76% of tamoxifen’s cance between the two groups with a 19,000 women in the STAR trial. on raloxifene received 60 mg/day. chemopreventative benefit, which trans- risk ratio of 1.22 (P = .12). The relative While tamoxifen proved significantly At an average follow-up of 8 years, the lates into at 38% reduction in invasive risk of 1.22 favors tamoxifen, but ralox- more effective in preventing invasive breast relative risk of invasive breast cancer on breast cancers,” Dr.
    [Show full text]
  • Effects of Biologically Active Metabolites of Tamoxifen on the Proliferation Kinetics of MCF-7 Human Breast Cancer Cells in Vitro
    [CANCER RESEARCH 43, 4618-4624, October 1983] Effects of Biologically Active Metabolites of Tamoxifen on the Proliferation Kinetics of MCF-7 Human Breast Cancer Cells in Vitro Roger R. Reddel, Leigh C. Murphy, and Robert L. Sutherland1 Ludwig Institute for Cancer Research (Sydney Branch), University of Sydney, Sydney, New South Wales 2006, Australia ABSTRACT tumor tissues of patients treated with tamoxifen is DMT, with 4OHT being present at much lower concentrations (1, 7,13, 25). The effects of two major metabolites of tamoxifen, /V-de- Prompted no doubt in part by the early misidentification of the methyltamoxifen (DMT) and 4-hydroxytamoxifen (4OHT), on major metabolite as 4OHT, there has been considerable interest MCF-7 Å“il proliferation and cell cycle kinetic parameters were in the antiestrogenic and antitumor activity of 4OHT (2, 3, 6,15, compared with those of the parent compound. All three com 16, 33). In contrast, there have been very few studies on the pounds produced dose-dependent decreases in the rate of cell biological activity of DMT (6, 33). proliferation which were accompanied by decreases in the per In the present study, we have attempted to answer the follow centage of S- and G2-M-phase cells. 4OHT was 100- to 167-fold ing questions. Do the metabolites DMT and 40HT differ from more potent than both tamoxifen and DMT in producing these tamoxifen in their actions on the proliferation and cell cycle effects, and this was correlated with their relative binding affini kinetics of human breast cancer cells? What are the relative ties (RBAs) for the cytoplasmic estrogen receptor (ER) (17/3- potencies of these 3 compounds in their actions on such cells in estradiol = 100, 4OHT = 41, tamoxifen = DMT = 2).
    [Show full text]
  • Chemotherapy Regimen: Tamoxifen
    Tamoxifen Chemotherapy Teaching The Center for Breast Cancer Mass General Cancer Center Center for Breast Cancer Topics to Discuss: • How Tamoxifen works • How Tamoxifen is taken • Storage, Handling, and Disposal • Drug Interactions • Side Effects & How to Manage • Supportive Care Resources • Your Breast Cancer Team • When to Call • Important Phone Numbers 2 What is TAMOXIFEN? • TAMOXIFEN (Nolvadex®) is an oral hormonal therapy used for hormone-sensitive breast cancers. • It works by blocking estrogen from binding to hormone receptors. This: • decreases the chance of breast cancer returning (recurrence) • decreases tumor size • delays tumors from spreading (progression) • Your care team will talk with you about how long you will need to take this therapy. – It is common to be on therapy for 5-10 years. 3 How is it taken? • TAMOXIFEN is a tablet you take by mouth. • Take one tablet (20 mg) once daily with or without food at the same time each day. – Do not take with grapefruit juice. • Swallow tablet whole with water. Do not break, chew, or crush your tablet. • If you miss a dose, skip the dose. Do not take 2 doses at the same time to make up for the missed dose. 4 Storing and Handling • Keep TAMOXIFEN in its original bottle or in a separate pill box – do not mix other medicines into the same pill box. • Store at room temperature in a dry location away from direct light. • Keep out of reach from children and pets. • Wash your hands before and after handling. – If someone else will be handling your TAMOXIFEN, have them wear gloves so they do not come into direct contact with the medicine.
    [Show full text]
  • Luteal Phase Deficiency: What We Now Know
    ■ OBGMANAGEMENT BY LAWRENCE ENGMAN, MD, and ANTHONY A. LUCIANO, MD Luteal phase deficiency: What we now know Disagreement about the cause, true incidence, and diagnostic criteria of this condition makes evaluation and management difficult. Here, 2 physicians dissect the data and offer an algorithm of assessment and treatment. espite scanty and controversial sup- difficult to definitively diagnose the deficien- porting evidence, evaluation of cy or determine its incidence. Further, while Dpatients with infertility or recurrent reasonable consensus exists that endometrial pregnancy loss for possible luteal phase defi- biopsy is the most reliable diagnostic tool, ciency (LPD) is firmly established in clinical concerns remain about its timing, repetition, practice. In this article, we examine the data and interpretation. and offer our perspective on the role of LPD in assessing and managing couples with A defect of corpus luteum reproductive disorders (FIGURE 1). progesterone output? PD is defined as endometrial histology Many areas of controversy Linconsistent with the chronological date of lthough observational and retrospective the menstrual cycle, based on the woman’s Astudies have reported a higher incidence of LPD in women with infertility and recurrent KEY POINTS 1-4 pregnancy losses than in fertile controls, no ■ Luteal phase deficiency (LPD), defined as prospective study has confirmed these find- endometrial histology inconsistent with the ings. Furthermore, studies have failed to con- chronological date of the menstrual cycle, may be firm the superiority of any particular therapy. caused by deficient progesterone secretion from the corpus luteum or failure of the endometrium Once considered an important cause of to respond appropriately to ovarian steroids.
    [Show full text]
  • Effect of Tamoxifen Or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer
    ANTICANCER RESEARCH 31: 1367-1372 (2011) Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer S.J. STANWAY1, C. PALMIERI2, F.Z. STANCZYK3, E.J. FOLKERD4, M. DOWSETT4, R. WARD2, R.C. COOMBES2, M.J. REED1† and A. PUROHIT1 1Oncology Drug Discovery Group, Section of Investigative Medicine, Imperial College London, Hammersmith Hospital, London W12 0NN, U.K.; 2Cancer Research UK Laboratories, Department of Oncology, Hammersmith Hospital, London W12 0NN, U.K.; 3Reproductive Endocrine Research Laboratory, University of Southern California, Keck School of Medicine, Women’s and Children’s Hospital, Los Angeles, CA, U.S.A.; 4Department of Biochemistry, Royal Marsden Hospital, London, SW3 6JJ, U.K. Abstract. Background: In postmenopausal women sulfate and dehydroepiandrosterone levels. Results: Neither estrogens can be formed by the aromatase pathway, which anastrozole nor tamoxifen had any significant effect on STS gives rise to estrone, and the steroid sulfatase (STS) route activity as measured in PBLs. Anastrozole did not affect which can result in the formation of estrogens and serum androstenediol concentrations. Conclusion: androstenediol, a steroid with potent estrogenic properties. Anastrozole and tamoxifen did not inhibit STS activity and Aromatase inhibitors, such as anastrozole, are now in serum androstenediol concentrations were not reduced by clinical use whereas STS inhibitors, such as STX64, are still aromatase inhibition. As androstenediol has estrogenic undergoing clinical evaluation. STX64 was recently shown properties, it is possible that the combination of an to block STS activity and reduce serum androstenediol aromatase inhibitor and STS inhibitor may give a therapeutic concentrations in postmenopausal women with breast cancer.
    [Show full text]
  • Comparison Between Two Methods of Ovulation Induction: Clomiphene Alone and Clomiphene +Tamoxifen in PCOS Patients
    Iranian Journal of Reproductive Medicine Vol. 2. No.2 pp:74-77, 2004 Comparison between Two Methods of Ovulation Induction: Clomiphene alone and Clomiphene +Tamoxifen in PCOS Patients Mohammad Ghafourzadeh, M.D.1, Mojgan Karimi M.D.2, Mohammad Ali Karimazadeh, M.D. 3, and Mahshid Bokai,B.S. 4 1,2,3,4 Shahid Sadoughi Univerisity of Medical Sciences and Health Services of Yazd, Iran. Background: Infertility affects about 10-15% of reproductive-age couples. About half the causes of infertility are female related and approximately 40% of the cases are caused by anovulation, mostly in PCO women. Objective: This study was conducted to determine and compare the effects of two drug treatment regimens: higher dose of clomiphene and a combination of lower dose of clomiphene and tamoxifen in treating infertile women with PCO. Materials and Methods: The study was a randomized clinical trial conducted on 100 infertile patients who referred to Yazd-Iran Infertility Clinic between the years 2001-2003. The patients were selected who had received at least 3 periods of clomiphene, but no pregnancy had occurred. They were randomly divided into two groups. In the first group, clomiphene was increased to 100 mg and the second group 20 mg of tamoxifen was added to 50 mg of clomiphene from day 5-9 of menstruation cycle. Infertility duration, duration of medicine used, PCT score, endometrial thickness, ovulation, and pregnancy rate were studied in both groups. Results: Ovulation rate in clomiphene group was 54.9%; Tamoxifen + clomiphene group was 73.5% without significant differences in both groups. (PV = 0.053).
    [Show full text]
  • The Woman with Postmenopausal Bleeding
    THEME Gynaecological malignancies The woman with postmenopausal bleeding Alison H Brand MD, FRCS(C), FRANZCOG, CGO, BACKGROUND is a certified gynaecological Postmenopausal bleeding is a common complaint from women seen in general practice. oncologist, Westmead Hospital, New South Wales. OBJECTIVE [email protected]. This article outlines a general approach to such patients and discusses the diagnostic possibilities and their edu.au management. DISCUSSION The most common cause of postmenopausal bleeding is atrophic vaginitis or endometritis. However, as 10% of women with postmenopausal bleeding will be found to have endometrial cancer, all patients must be properly assessed to rule out the diagnosis of malignancy. Most women with endometrial cancer will be diagnosed with early stage disease when the prognosis is excellent as postmenopausal bleeding is an early warning sign that leads women to seek medical advice. Postmenopausal bleeding (PMB) is defined as bleeding • cancer of the uterus, cervix, or vagina (Table 1). that occurs after 1 year of amenorrhea in a woman Endometrial or vaginal atrophy is the most common cause who is not receiving hormone therapy (HT). Women of PMB but more sinister causes of the bleeding such on continuous progesterone and oestrogen hormone as carcinoma must first be ruled out. Patients at risk for therapy can expect to have irregular vaginal bleeding, endometrial cancer are those who are obese, diabetic and/ especially for the first 6 months. This bleeding should or hypertensive, nulliparous, on exogenous oestrogens cease after 1 year. Women on oestrogen and cyclical (including tamoxifen) or those who experience late progesterone should have a regular withdrawal bleeding menopause1 (Table 2).
    [Show full text]
  • Integrating Personalization of Treatment with Tamoxifen Into
    ical C eut are ac & m H r e a a h l t P h f S o y Journal of l s a t n e r m Ibrahim, J Pharma Care Health Sys 2016, 3:2 u s o J DOI: 10.4172/2376-0419.1000162 ISSN: 2376-0419 Pharmaceutical Care & Health Systems Research Article Open Access Integrating Personalization of Treatment with Tamoxifen into Pharmacy Practice Via Clinical Pharmacist Role in Therapy Management Nagwa Ibrahim* Department of Pharmaceutical Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia *Corresponding author: Nagwa Ibrahim, Department of Pharmaceutical Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia, Tel: 00966-4777714; E- mail: [email protected] Received date: Jun 14, 2016; Accepted date: Jun 20, 2016; Published date: Jun 24, 2016 Copyright: © 2016 Ibrahim N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract The concept of individualized therapy is intended to deliver the right therapy to the right patient at the right time. Personalization of treatment aims to shift health care from population based or empirical approach to scientifically tailored approach. Pharmacogenenetics use the genetic information such as DNA sequence, gene expression and copy number to explain the inter-individual differences in drug metabolism (pharmacokinetics) and physiological drug response (pharmacodynamics), to predict the efficacy and toxicity of drugs and to identify responders and non responders to a specific drug. Success of the personalized medicine depends on the identification of predictive biomarkers and development of accurate and reliable diagnostics.
    [Show full text]
  • Gynecologic Pathology Grossing Guidelines Specimen Type
    Gynecologic Pathology Grossing Guidelines Specimen Type: TOTAL HYSTERECTOMY and SALPINGO-OOPHRECTOMY (for TUMOR) Gross Template: Labeled with the patient’s name (***), medical record number (***), designated “***”, and received [fresh/in formalin] is a *** gram [intact/previously incised/disrupted] [total/ supracervical hysterectomy/ total hysterectomy and bilateral salpingectomy, hysterectomy and bilateral salpingo-oophrectomy]. The uterus weighs [***grams] and measures *** cm (cornu-cornu) x *** cm (fundus-lower uterine segment) x *** cm (anterior - posterior). The cervix measures *** cm in length x *** cm in diameter. The endometrial cavity measures *** cm in length, up to *** cm wide. The endometrium measures *** cm in average thickness. The myometrium ranges from *** to *** cm in thickness. The right ovary measures *** x *** x *** cm. The left ovary measures *** x *** x *** cm. The right fallopian tube measures *** cm in length [with/without] fimbriae x *** cm in diameter, with a *** cm average luminal diameter. The left fallopian tube measures *** cm in length [with/without] fimbriae x *** cm in diameter, with a *** cm average luminal diameter. The serosa is [pink, smooth, glistening, unremarkable/has adhesions]. The endometrium is tan-red and remarkable for [describe lesion- location (fundus, corpus, lower uterine segment); size (***x***cm in area); color; consistency; configuration (solid, papillary, exophytic, polypoid)]. Sectioning reveals the mass has a [describe cut surface-solid, cystic, etc.]. The mass extends [less than/ greater than] 50% into the myometrium (the mass involves *** cm of the wall where the wall measures *** cm in thickness, in the [location]). The mass [does/does not] involve the lower uterine segement and measures *** cm from the cervical mucosa. The myometrium is [tan-yellow, remarkable for trabeculations, cysts, leiyomoma- (location, size)].
    [Show full text]
  • The Uterus and the Endometrium Common and Unusual Pathologies
    The uterus and the endometrium Common and unusual pathologies Dr Anne Marie Coady Consultant Radiologist Head of Obstetric and Gynaecological Ultrasound HEY WACH Lecture outline Normal • Unusual Pathologies • Definitions – Asherman’s – Flexion – Osseous metaplasia – Version – Post ablation syndrome • Normal appearances – Uterus • Not covering congenital uterine – Cervix malformations • Dimensions Pathologies • Uterine – Adenomyosis – Fibroids • Endometrial – Polyps – Hyperplasia – Cancer To be avoided at all costs • Do not describe every uterus with two endometrial cavities as a bicornuate uterus • Do not use “malignancy cannot be excluded” as a blanket term to describe a mass that you cannot categorize • Do not use “ectopic cannot be excluded” just because you cannot determine the site of the pregnancy 2 Endometrial cavities Lecture outline • Definitions • Unusual Pathologies – Flexion – Asherman’s – Version – Osseous metaplasia • Normal appearances – Post ablation syndrome – Uterus – Cervix • Not covering congenital uterine • Dimensions malformations • Pathologies • Uterine – Adenomyosis – Fibroids • Endometrial – Polyps – Hyperplasia – Cancer Anteflexed Definitions 2 terms are described to the orientation of the uterus in the pelvis Flexion Version Flexion is the bending of the uterus on itself and the angle that the uterus makes in the mid sagittal plane with the cervix i.e. the angle between the isthmus: cervix/lower segment and the fundus Anteflexed < 180 degrees Retroflexed > 180 degrees Retroflexed Definitions 2 terms are described
    [Show full text]